AU2019282316B2 - Compositions and methods for diagnosis and treatment of cancer - Google Patents

Compositions and methods for diagnosis and treatment of cancer Download PDF

Info

Publication number
AU2019282316B2
AU2019282316B2 AU2019282316A AU2019282316A AU2019282316B2 AU 2019282316 B2 AU2019282316 B2 AU 2019282316B2 AU 2019282316 A AU2019282316 A AU 2019282316A AU 2019282316 A AU2019282316 A AU 2019282316A AU 2019282316 B2 AU2019282316 B2 AU 2019282316B2
Authority
AU
Australia
Prior art keywords
cys
arg
thr
gly
edb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019282316A
Other languages
English (en)
Other versions
AU2019282316A1 (en
Inventor
Matin DANESCHDAR
Markus Fiedler
Bonny Gaby LUI
Ugur Sahin
Nadja SALOMON
Hans-Ulrich Schmoldt
Joycelyn WÜSTEHUBE-LAUSCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of AU2019282316A1 publication Critical patent/AU2019282316A1/en
Application granted granted Critical
Publication of AU2019282316B2 publication Critical patent/AU2019282316B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
AU2019282316A 2018-06-08 2019-06-06 Compositions and methods for diagnosis and treatment of cancer Ceased AU2019282316B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/EP2018/065205 2018-06-08
PCT/EP2018/065205 WO2019233605A1 (en) 2018-06-08 2018-06-08 Compositions and methods for diagnosis and treatment of cancer
PCT/EP2019/064872 WO2019234190A1 (en) 2018-06-08 2019-06-06 Compositions and methods for diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
AU2019282316A1 AU2019282316A1 (en) 2020-12-24
AU2019282316B2 true AU2019282316B2 (en) 2023-07-20

Family

ID=62636178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019282316A Ceased AU2019282316B2 (en) 2018-06-08 2019-06-06 Compositions and methods for diagnosis and treatment of cancer

Country Status (10)

Country Link
US (2) US11673939B2 (https=)
EP (1) EP3802585A1 (https=)
JP (1) JP7466466B2 (https=)
KR (2) KR20240142617A (https=)
CN (2) CN112424220A (https=)
AU (1) AU2019282316B2 (https=)
BR (1) BR112020024034A2 (https=)
CA (1) CA3101246A1 (https=)
MX (1) MX2020013205A (https=)
WO (2) WO2019233605A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022597A1 (en) * 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111302A1 (en) 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CA2741040C (en) * 2008-10-20 2015-09-22 Gwangju Institute Of Science And Technology Bipodal-peptide binder
CA2822938A1 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
AU2014252354A1 (en) * 2013-04-11 2015-11-19 Merck Patent Gmbh Potent inhibitors of human matriptase derived from McotI-II variants
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022597A1 (en) * 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use

Also Published As

Publication number Publication date
JP2021526808A (ja) 2021-10-11
JP7466466B2 (ja) 2024-04-12
EP3802585A1 (en) 2021-04-14
US20210246191A1 (en) 2021-08-12
CN116987180A (zh) 2023-11-03
WO2019233605A1 (en) 2019-12-12
MX2020013205A (es) 2021-02-26
KR20210020006A (ko) 2021-02-23
BR112020024034A2 (pt) 2021-02-23
CA3101246A1 (en) 2019-12-12
US20240002471A1 (en) 2024-01-04
CN112424220A (zh) 2021-02-26
WO2019234190A1 (en) 2019-12-12
NZ770391A (en) 2024-09-27
KR20240142617A (ko) 2024-09-30
US11673939B2 (en) 2023-06-13
AU2019282316A1 (en) 2020-12-24
US12516104B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
EP3271385B1 (en) Compositions and methods for diagnosis and treatment of cancer
JP5841046B2 (ja) 制御された血清中薬物動態を有するヒトタンパク質スキャフォールド
JP2015193653A (ja) プロタンパク質およびその使用方法
US12516104B2 (en) Compositions and methods for diagnosis and treatment of cancer
KR20240139054A (ko) 가교 항체
US20240115717A1 (en) Chlorotoxin derivatives and use thereof
HK1242717B (en) Compositions and methods for diagnosis and treatment of cancer
HK1242717A1 (en) Compositions and methods for diagnosis and treatment of cancer
HK1247931B (zh) 用於诊断和治疗癌症的组合物和方法
NZ734680B2 (en) Compositions and methods for diagnosis and treatment of cancer
KR20260045855A (ko) 항-Trop2 항체, 상기 항체를 포함하는 접합체 및 이의 응용
BR112017018522B1 (pt) Peptídeo de ligação a seprase; agente de ligação a seprase compreendendo o dito peptídeo de ligação a seprase; ácido nucleico recombinante, o qual codifica o dito peptídeo de ligação a seprase; método para ensaiar a presença e / ou quantidade de seprase numa amostra; método para diagnóstico, detecção e monitoração do câncer em um paciente, composição farmacêutica e uso dos mesmos
JP2025528414A (ja) インテグリンα１０抗体薬物複合体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired